Literature DB >> 9607856

GB virus C infection in patients with primary antibody deficiency.

A Morris1, A D Webster, D Brown, T J Harrison, G Dusheiko.   

Abstract

Sera from 77 patients with common variable immunodeficiency (CVID) were tested for GB virus C (GBV-C) RNA, because they are prone to unexplained chronic hepatitis, and from 28 patients with X-linked agammaglobulinemia (XLA) who have a similar primary antibody deficiency but are not prone to hepatitis. Eight CVID and 8 XLA patients were positive; 6 positive CVID and 3 XLA patients had abnormal liver enzymes, explained in 3 by either hepatitis B or C virus infection. Most patients tested had antibodies to the E2 antigen of GBV-C, apparently passively acquired from their immunoglobulin therapy. The high prevalence of GBV-C viremia in CVID and XLA patients is probably explained by their long-term exposure to blood products. Our data indicate that GBV-C does not cause chronic hepatitis in immunocompromised XLA patients and is not the cause of chronic non-B or -C hepatitis in the majority of CVID patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607856     DOI: 10.1086/517430

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 2.  GB virus C/hepatitis G virus (GBV-C/HGV): still looking for a disease.

Authors:  M Sathar; P Soni; D York
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

Review 3.  Infectious Complications Reporting in Common Variable Immunodeficiency: A Systematic Review and Meta-analysis.

Authors:  Hamed Zainaldain; Fatema Sadaat Rizvi; Hosein Rafiemanesh; Mahla Alizadeh; Mahnaz Jamee; Sara Mohammadi; Fatemeh Kiaee; Hamed Mohammadi; Farhad Babaie; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi; Gholamreza Azizi
Journal:  Oman Med J       Date:  2020-07-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.